Hjem › Steatotisk leversykdom › Florida
Kliniske studier for Steatotisk leversykdom i Florida
20 studier for Steatotisk leversykdom søker deltakere på steder i Florida.
Byer i Florida
- Miami16 studier
- Orlando9 studier
- Hialeah9 studier
- Ocala8 studier
- Cape Coral6 studier
- Sarasota6 studier
- West Palm Beach5 studier
- Jacksonville5 studier
- Brandon4 studier
- Doral4 studier
- Spring Hill4 studier
- Homestead4 studier
- The Villages3 studier
- Boca Raton3 studier
- Deltona3 studier
- St. Petersburg3 studier
- Gainesville3 studier
- Kendall3 studier
- Town 'n' Country3 studier
- Lakeland3 studier
- Melbourne3 studier
Offisiell studietekst (engelsk)
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Miami
- GSK Investigational Site, Miami
- GSK Investigational Site, Ocala
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 30. sep. 2026 · NCT07704892A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Miami
- GSK Investigational Site, Miami
- GSK Investigational Site, Ocala
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 30. sep. 2026 · NCT07701993A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
- Health Awareness, Inc, Jupiter
- Evolution Clinical Trials, Miami
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 29. sep. 2026 · NCT07527910Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
- University of Miami Health System, Miami
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT05832229A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- Evolution Clinical Trials, Hialeah Gardens
- Health Awareness, inc., Jupiter
- Genoma Research Group, Inc., Miami
- og 2 flere
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- K2 Medical Research WINTER GARDEN, Clermont
- K2 Medical Research - Daytona Beach, Daytona Beach
- Care Access - Delray Beach, Delray Beach
- og 20 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Bradenton
- Akero Clinical Study Site, Brandon
- Akero Clinical Study Site, Cutler Bay
- og 23 flere
RekruttererFase 3
Alder 18 til 80 · Alle kjønn · Oppdatert 21. sep. 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Boynton Beach
- GSK Investigational Site, Cape Coral
- GSK Investigational Site, Clermont
- og 19 flere
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 17. sep. 2026 · NCT07221188A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Synergy Healthcare, Bradenton
- Synergy Healthcare, Bradenton
- Health Awareness, Inc., Jupiter
- og 6 flere
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 9. sep. 2026 · NCT07288138A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Brandon
- 89bio Clinical Study Site, Clermont
- 89bio Clinical Study Site, Fort Myers
- og 15 flere
RekruttererFase 3
Alder 18 til 80 · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Clermont
- 89bio Clinical Study Site, Fort Myers
- 89bio Clinical Study Site, Gainesville
- og 15 flere
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06419374Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis
- AdventHealth Translational Research Institute, Orlando
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 25 til 55 · Alle kjønn · Oppdatert 12. aug. 2026 · NCT06993454A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Brandon
- GSK Investigational Site, Miami
- GSK Investigational Site, Miami Lakes
RekruttererFase 2
Alder 18 til 70 · Alle kjønn · Oppdatert 3. aug. 2026 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Boynton Beach
- GSK Investigational Site, Cape Coral
- GSK Investigational Site, Clermont
- og 20 flere
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 27. jul. 2026 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Miami
- GSK Investigational Site, Viera
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 8. jul. 2026 · NCT06920043A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
- GSK Investigational Site, Tampa
RekruttererFase 1
Alder 18 til 70 · Alle kjønn · Oppdatert 9. jun. 2026 · NCT07358546A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Genoma Research Group, Inc, Miami
- Med Research of Florida, LLC, Miami
RekruttererFase 1/2Frivillige helsepersonell ønskes velkommen
Alder 18 til 75 · Alle kjønn · Oppdatert 16. apr. 2026 · NCT05648214Evaluation of Non-Invasive Tests for Metabolic Liver Disease
- Clinical Pharmacology of Miami, Miami
RekruttererObservasjonsstudie
Alder 18 til 75 · Alle kjønn · Oppdatert 14. aug. 2025 · NCT07122700Low-Dose Pioglitazone in Patients With NASH (AIM 2)
- University of Florida, Gainesville
RekruttererFase 2
Alder 21 til 75 · Alle kjønn · Oppdatert 4. apr. 2025 · NCT04501406AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
- AdventHealth Translational Research Institute, Orlando
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 18 og eldre · Alle kjønn · Oppdatert 13. mar. 2025 · NCT04807868Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.